You are viewing the site in preview mode

Skip to main content

Table 1 Phase 3 clinical trials of NOACs: study design and outcomes

From: A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits

Trial name Trial design No. of patients Outcomes (annual rate vs. comparator,a %/y)
Stroke/Systemic embolism All-cause mortalityb Major bleedingb Intracranial hemorrhageb
RE-LYc (dabigatran) [23, 31] PROBE designd N = 18113 Dabigatran 150 mg bid: n = 6076 Dabigatran 150 mg: RR 0.66 (95 % CI 0.53, 0.82; p < 0.001 for superiority) Dabigatran 150 mg: RR 0.88 (95 % CI 0.77, 1.00; p = 0.051) Major bleeding: Dabigatran 150 mg: RR 0.93 (95 % CI 0.81, 1.07; p = 0.31) Dabigatran 150 mg: RR 0.40 (95 % CI 0.27, 0.60; p < 0.001)
Dabigatran 110 mg bid: n = 6015 Dabigatran 110 mg: RR 0.91 (95 % CI 0.74, 1.11; p < 0.001 for noninferiority) Dabigatran 110 mg: RR 0.91 (95 % CI 0.80, 1.03; p = 0.13) Dabigatran 110 mg: RR 0.80 (95 % CI 0.69, 0.93; p = 0.003) Dabigatran 110 mg: RR 0.31 (95 % CI 0.20, 0.47; p < 0.001)
Warfarin (adjusted dose, target INR 2.0–3.0): n = 6022     
ROCKET-AF (rivaroxaban) [25] Randomized, double-blind, double-dummy, noninferiority trial N = 14264 Rivaroxaban 20 mg/d: n = 7131   HR 0.85 (95 % CI 0.70, 1.02; p = 0.07) Major and CRNM bleeding: HR 1.03 (95 % CI 0.96, 1.11; p = 0.44) HR 0.67 (95 % CI 0.47, 0.93; p = 0.02)
Warfarin (adjusted dose, target INR 2.0–3.0): n = 7133 HR 0.88 (95 % CI 0.75, 1.03; p < 0.001 for noninferiority; p = 0.12 for superiority)e   Major bleeding: HR 1.04 (95 % CI 0.90, 1.20; p = 0.58)  
ENGAGE AF-TIMI 48 (edoxaban) [26] Randomized, double-blind, double-dummy, noninferiority trial N = 21105 Edoxaban 60 mg once daily: n = 7035 Edoxaban 60 mg: HR 0.79 (97.5 % CI 0.63, 0.99; p < 0.001 for noninferiority; p = 0.08 for superiority)f Edoxaban 60 mg: HR, 0.92 (95 % CI. 0.83, 1.01; p = 0.08) Major bleeding: Edoxaban 60 mg: HR 0.80 (95 % CI 0.71, 0.91; p < 0.001) Edoxaban 60 mg: HR 0.47 (95 % CI 0.34, 0.63; p < 0.001)
Edoxaban 30 mg once daily: n = 7034 Edoxaban 30 mg: HR 1.07 (97.5 % CI 0.87, 1.31; p = 0.005 for noninferiority; p = 0.10 for superiority)f Edoxaban 30 mg: HR, 0.87 (95 % CI, 0.79, 0.96; p = 0.006) Edoxaban 30 mg: HR 0.47 (95 % CI 0.41, 0.55; p < 0.001) Edoxaban 30 mg: HR 0.30 (95 % CI 0.21, 0.43; p < 0.001)
Warfarin (adjusted dose, target INR 2.0–3.0): n = 7036     
ARISTOTLE (apixaban) [24] Randomized, double-blind, double-dummy, noninferiority trial N = 18201 Apixaban 5 mg bid: n = 9120 HR 0.79 (95 % CI 0.66, 0.95; p < 0.001 for noninferiority; p = 0.01 for superiority) HR 0.89 (95 % CI 0.80, 0.998; p = 0.047) Major bleeding: HR 0.69 (95 % CI 0.60, 0.80; p < 0.001) HR, 0.42 (95 % CI, 0.30, 0.58; p < 0.001)
Warfarin (adjusted dose, target INR 2.0–3.0): n = 9081     
AVERROES (apixaban) [32] Randomized, double-blind, double-dummy, superiority trialg N = 5599 Apixaban 5 mg bid: n = 2808 HR 0.45 (95 % CI 0.32, 0.62; p < 0.001) HR 0.79 (95 % CI 0.62, 1.02; p = 0.07) Major bleeding: HR 1.13 (95 % CI 0.74, 1.75; p = 0.57) HR 0.85 (95 % CI 0.38, 1.90; p = 0.69)
Aspirin 81–324 mg/d: n = 279     
  1. bid twice daily, CI confidence interval, CRNM clinically relevant nonmajor, HR hazard ratio, INR international normalized ratio, ITT intention-to-treat, NOAC novel oral anticoagulant, PROBE prospective, randomized, open, blinded end-point, RR relative risk
  2. aNOACs were compared with warfarin in the RE-LY, ROCKET-AF, ENGAGE AF-TIMI 48 and ARISTOTLE trials and with aspirin in the AVERROES trial
  3. bp values are for superiority
  4. cValues for RE-LY are given as RR
  5. dPROBE design
  6. eITT population
  7. fModified ITT (mITT) population
  8. gThis study was terminated early due to treatment benefit in favor of apixaban
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us